|
|
||||||||
Errata |
In "Effectiveness of Treatment Strategies of Some Women With Pelvic Inflammatory Disease: A Randomized Trial" by R. B. Ness, G. Trautmann, H. E. Richter, H. Randall, J. F. Peipert, D. B. Nelson, et al (Obstet Gynecol 2005;106:573), the authors presented 7-year followup results from the PEACH (Pelvic Inflammatory Disease Evaluation and Clinical Health) study. The authors concluded that, among women with mild-to-moderate pelvic inflammatory disease (PID), there were no differences after randomization to outpatient versus inpatient treatment in reproductive outcomes among subgroups of women by race, age, previous PID, presence or absence of cervicitis, or PIDT3 severity. The authors discovered that, in the analyses focused on single strata, they inadvertently combined two strata when calculating point estimates. The authors apologize for their error. The corrected analyses verify their original interpretation. The corrected tables, presented on pages 14235, confirm that in no subgroup of women with PID did outpatient treatment assignment adversely impact the proportion having one or more pregnancies, live births, ectopic pregnancies, infertility, PID recurrence, or chronic pelvic pain.
|
|
|
|
2 consecutive visits
4 months apart" and "HPV16 DNA detection at > 1 visit" should be "HPV16 DNA detection at
1 visit." In "Extracorporeal Membrane Oxygenation Therapy for Circulatory Arrest Due to Postpartum Hemorrhage" by L. Reyftmann, E. Morau, H. Dechaud, J.-M. Frapier, and B. Hedon (Obstet Gynecol 2006;107: 5114), the names of the final three authors appeared as "Dechaud Herve, MD, PhD, Frapier Jean-Marc, MD, PhD, and Hedon Bernard, MD." Their names should have appeared as follows: "Herve Dechaud, MD, PhD, Jean-Marc Frapier, MD, PhD, and Bernard Hedon, MD."
In "SILCS Diaphragm: Postcoital Testing of a New Single-Size Contraceptive Diaphragm"* by J.L. Schwartz, C.K. Mauck, R.W. Rountree, S.A. Ballagh, M.D. Creinin, and M. Kilbourne-Brook (Obstet Gynecol 2006;107:12S), the term "K-Y Jelly" was erroneously replaced with "petroleum jelly." The corrected abstract is reprinted in its entirety below.
OBJECTIVE:
To compare the effectiveness of a new, single-size silicone contraceptive diaphragm developed by PATH used with either spermicide (2% N-9) or K-Y jelly to prevent sperm from penetrating midcycle cervical mucus.
METHODS:
A crossover postcoital testing in 33 healthy, sexually active women not at risk for pregnancy due to previous bilateral tubal ligation or salpingectomy was conducted at Eastern Virginia Medical School and University of Pittsburgh Medical Center. First, a baseline postcoital testing was performed without a device to verify normal measures. Qualified participants underwent up to 2 test cycles using the SILCS diaphragm (metal spring) with either N-9 or K-Y jelly (order randomized). Some participants underwent a third test cycle using the SILCS diaphragm (polymer spring) with N-9. Cycles were completed as follows: baseline (15), SILCS diaphragm (metal spring) with N-9 (13), SILCS diaphragm (metal spring) with K-Y jelly (12), and SILCS diaphragm (polymer spring) with N-9 (8).
RESULTS:
The SILCS diaphragm (metal or polymer spring) with N-9 reduced the average number of pro-gressively motile sperm per high power field from a baseline of 12.5 to 0. The SILCS diaphragm (metal spring) with K-Y jelly reduced the number of progressively motile sperm per high power field to 0.5.
CONCLUSION:
Results from this most recent postcoital testing indicate that the current SILCS diaphragm design with the polymer spring and used with N-9 performed well and is accept-able for contraceptive effectiveness testing. The less expensive polymer spring, which is easier to manufacture, will replace the metal spring found in standard diaphragms.
Footnotes
* This document includes a discussion of use of a product that is unapproved by the U.S. Food and Drug Administration. ![]()
| ||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |